Will ADMA's days sales outstanding (DSO) remain above 90 days through H1 2026?

The question asks if DSO stays ABOVE 90 days through both Q1 and Q2 2026. Management explicitly promised improvement over the course of 2026 and hired a new CFO focused on working capital. However, structural factors work against rapid DSO improvement: 87% AR concentration from two customers, specialty biologic payment cycles, and the McKesson channel is just ramping. DSO improvement typically lags by 2-3 quarters after management action. The new CFO started recently and working capital optimization takes time to show in reported numbers. Slight lean toward YES (DSO remains elevated).

Management addressing DSO on earnings calls typically signals genuine intent to improve. The specific language about rightsizing of inventory, AR, etc., normalized towards the middle/back part of the year suggests management itself expects H1 to remain elevated. This is essentially management guidance that DSO will not normalize until H2 2026. If management is being honest about the timeline, YES is the expected outcome for H1. The counter-argument is that management may be setting conservative expectations. Near coin-flip, slight lean YES.

ADMA DSO issue is structural reflecting customer concentration (BioCare/CuraScript = 87% AR) and specialty biologic payment terms. Even with McKesson onboarding, channel diversification sufficient to move DSO below 90 days requires significant volume shift. The ASCENIV growth trajectory (51% YoY) will continue generating new AR faster than collections normalize. Rapid revenue growth mechanically elevates DSO unless collection speed improves proportionally. I expect DSO remains above 90 in at least Q1, making both quarters above 90 moderately likely.

The 90-day DSO threshold through both Q1 and Q2 is quite likely to be met (DSO stays above 90). Three structural factors: (1) BioCare/CuraScript concentration will not change materially in 6 months, (2) ASCENIV rapid growth generates proportionally more AR, (3) McKesson is too early in ramp to offset. Management own language points to H2 normalization, not H1. The new CFO mandate on working capital optimization is a medium-term initiative, not a quick fix. DSO above 90 through H1 is the base case.

DSO improvement requires either faster collections from existing customers or meaningful channel diversification. Neither is likely to materialize fully in Q1-Q2 2026. BioCare and CuraScript payment terms are presumably contractual and not easily renegotiated in 6 months. McKesson channel is new and will start small. The question resolves YES if BOTH quarters show DSO above 90 -- the AND condition makes this moderately likely since even partial improvement in one quarter might not breach 90. However, there is a chance Q2 shows early improvement given the CFO focus. Slight lean YES.

The combination of management own guided timeline (H2 normalization) and the structural nature of the DSO issue makes sustained above-90 through H1 quite probable. The short seller controversy may actually slow any customer payment renegotiations as counterparties gain leverage. ADMA specialty positioning means limited negotiating power on payment terms with major distributors. The AND condition (both quarters) slightly increases probability since one bad quarter is enough for YES. Moderate confidence in YES.

Structural DSO issues do not resolve in one quarter. Management guided H2 normalization. Customer concentration at 87% AR will not change fast. New CFO just started. Clear lean toward DSO remaining above 90 through H1 2026.

87% AR concentration from two customers creates a structural floor on DSO. McKesson channel too new to help. Revenue growth at 51% for ASCENIV generates more AR faster than collections can improve. Probable that DSO stays above 90 through both quarters.

Management explicitly expects improvement later in 2026. New CFO working capital focus is right but takes time. DSO above 90 through H1 is the expected case based on management own guidance. Some chance of early surprise improvement in Q2 keeps probability moderate rather than high.